The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
Clinical trial NCT06255795 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06255795
- Sponsor
- Ruijin Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-15
- Primary completion
- 2026-12-31
- Enrollment
- 142
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.